We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

222 hedge funds and large institutions have $2.25B invested in Summit Therapeutics in 2026 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 83 increasing their positions, 49 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 49

57% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 37

9% more capital invested

Capital invested by funds: $2.06B → $2.25B (+$192M)

8% more funds holding

Funds holding: 206 → 222 (+16)

0.06% more ownership

Funds ownership: 15.27% → 15.34% (+0.06%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

15% less call options, than puts

Call options by funds: $39.9M | Put options by funds: $46.7M

Holders
222
Holders Change
+16
Holders Change %
+7.77%
% of All Funds
2.73%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
58
Increased
83
Reduced
49
Closed
37
Calls
$39.9M
Puts
$46.7M
Net Calls
-$6.79M
Net Calls Change
+$13.4M

Top Buyers

1
UBS Group
UBS Group
Switzerland
+$45.4M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$29.5M
3
SCM
Superstring Capital Management
New York
+$14.4M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.7M
5
Morgan Stanley
Morgan Stanley
New York
+$11.7M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$40.6M
2
Citadel Advisors
Citadel Advisors
Florida
-$32.9M
3
PCMH
Polymer Capital Management (HK)
Hong Kong
-$20.8M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$17.7M
5
SC
Sculptor Capital
New York
-$6.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$11M +$859K +53,113 +10%
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$10.4M +$8.05M +498,037 +990%
CS
28
Candriam SCA
Luxembourg
$10.3M – – –
Invesco
29
Invesco
Georgia
$9.97M +$1.05M +64,802 +14%
Marshall Wace
30
Marshall Wace
United Kingdom
$9.01M +$7.69M +475,241 New
Citadel Advisors
31
Citadel Advisors
Florida
$8.38M -$32.9M -2,033,965 -82%
AQR Capital Management
32
AQR Capital Management
Connecticut
$8.11M +$1.39M +85,887 +24%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$7.67M +$824K +50,923 +14%
Tudor Investment Corp
34
Tudor Investment Corp
Connecticut
$7.3M -$616K -38,096 -9%
Wellington Management Group
35
Wellington Management Group
Massachusetts
$6.88M +$5.87M +362,858 New
QF
36
QVT Financial
New York
$6.84M – – –
Nomura Holdings
37
Nomura Holdings
Japan
$5.95M -$3.69M -228,253 -42%
EFM
38
E Fund Management
China
$5.91M +$5.04M +311,825 New
Goldman Sachs
39
Goldman Sachs
New York
$5.89M -$2.83M -174,838 -36%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$4.91M -$465K -28,736 -10%
ECM
41
ExodusPoint Capital Management
New York
$4.86M +$4.14M +256,255 New
N
42
Nuveen
North Carolina
$4.63M +$184K +11,350 +5%
Deutsche Bank
43
Deutsche Bank
Germany
$4.51M – – –
Schroder Investment Management Group
44
Schroder Investment Management Group
United Kingdom
$4.27M – – –
WP
45
Woodline Partners
California
$4.07M – – –
Citigroup
46
Citigroup
New York
$3.78M +$1.12M +69,207 +53%
GAM
47
Griffin Asset Management
New York
$3.64M -$59.4K -3,675 -2%
CUAMC
48
China Universal Asset Management Company
China
$2.61M +$263K +16,289 +13%
PCMH
49
Polymer Capital Management (HK)
Hong Kong
$2.52M -$20.8M -1,288,121 -91%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$2.47M +$288K +17,800 +16%
1
2
3 4 5

SMMT Hedge Fund Activity: Q1 2026 in Review

222 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2026, worth a combined $2.25B — up 9.3% from $2.06B a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new SMMT positions and 37 closed out — a net gain of 21 holders — while 83 added to existing stakes and 49 trimmed.

The largest buyer was UBS Group, adding an estimated $45.4M. The largest seller was Fidelity Investments, cutting an estimated $40.6M.

  • 222 institutional investors held Summit Therapeutics (SMMT) as of Q1 2026, up from 206 in Q4 2025.
  • Funds reported $2.25B of Summit Therapeutics stock for Q1 2026, up 9.3% quarter-over-quarter.
  • 58 funds opened new Summit Therapeutics positions in Q1 2026 and 37 closed out, a net change of +21 holders.
  • The largest Summit Therapeutics buyer in Q1 2026 was UBS Group, an estimated $45.4M added.
  • The largest Summit Therapeutics seller in Q1 2026 was Fidelity Investments, an estimated $40.6M sold.

Based on aggregated 13F filings for Q1 2026.